<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47989">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02481466</url>
  </required_header>
  <id_info>
    <org_study_id>REB # 14-316</org_study_id>
    <secondary_id>FRN 130278</secondary_id>
    <secondary_id>FRN 129920</secondary_id>
    <nct_id>NCT02481466</nct_id>
  </id_info>
  <brief_title>The Combined Portfolio Diet and Exercise Study</brief_title>
  <acronym>PortfolioEx</acronym>
  <official_title>The First Cross-Canada Trial of the Nutrition Trialists' Network--Enhanced Dietary Portfolio and Exercise on Arterial Damage (MRI-Enhanced Dietary Portfolio Plus Exercise on Cardiovascular Risk)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Michael's Hospital, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a dietary portfolio of
      cholesterol-lowering foods (viscous fibres, soy protein, plant sterols and nuts) further
      enhanced by increased levels of monounsaturated fatty acids (MUFA) and low glycemic index
      foods; together with a structured exercise program reduce the progression of carotid and
      coronary atheromatous lesions, Low density lipoprotein-cholesterol (LDL-C), and blood
      pressure, while reducing the number of individuals requiring statins.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Presently in Canada, 29% of deaths are due to cardiovascular disease (CVD), costing $20.9
      billion annually. The investigators have, therefore, brought together an unique network of
      investigators at different stages in their careers with a range of disciplines (nutrition,
      cardiology, diabetes, exercise physiology, imaging, physics, clinical trials, statistics,
      laboratory medicine, primary care, genetics, psychology, knowledge translation (KT),
      epidemiology), and with international recognition, experience and connections, to undertake
      a Canada-wide, multi-centre study which will test the ability of an effective
      cholesterol-lowering diet (dietary portfolio) and an exercise program, developed at Laval
      University, over 3 years to reduce the progression of plaque build-up in the carotid artery
      as assessed by Magnetic Resonance Imaging (MRI) in individuals with hypercholesterolemia and
      or type 2 diabetes. The dietary portfolio which has been proven in many of our studies to be
      an effective cholesterol-lowering diet will be enhanced to include features from other
      dietary strategies which the investigators have tested or developed; such as high
      monounsaturated fat (from Mediterranean diet) (CMAJ 2010) and low glycemic index foods (JAMA
      2008). The investigators plan to recruit194 (approximately 200) men and postmenopausal
      women, who have measurable thickening (as assessed by ultrasound) due to plaque build up in
      the carotid arteries, in a 1.5 year period for this 3 year study. Ultrasound selection will
      be of individuals with intima-media thickness (IMT) &gt;1mm as relevant arterial thickening to
      ensure a relatively low risk for the majority of the group, yet with some measurable
      arterial thickening. Those selected will be randomly assigned to receive advice on either a
      dietary Portfolio Plus diet and increased physical activity (test) or the DASH-like diet
      with routine physical activity (control). The results of the study will have a major
      influence on dietary and exercise guidelines for coronary heart disease (CH risk reduction
      and provide evidence for the larger international trial that will focus on hard endpoints,
      myocardial infarction (MI) and CHD events). It is hoped that this cohort of participants
      will continue on and form part of the planned 9 year hard end point (MACE) study if funded.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 25, 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline of the maximum vessel wall volume of the carotid arteries by MRI at year 3</measure>
    <time_frame>At months 0 and 36</time_frame>
    <description>MRI imaging assessment of the carotid arteries will be done at baseline and year 3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coronary atheroma in the large vessels by MRI at year 3</measure>
    <time_frame>At months 0 and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid rich necrotic core by MRI at year 3</measure>
    <time_frame>At months 0 and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intra plaque hemorrhage by MRI at year 3</measure>
    <time_frame>At months 0 and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure and pulse rate</measure>
    <time_frame>At months 0, 12 and 36</time_frame>
    <description>This is a composite measure that would by done using an automatic digital BP monitor which simultaneously measures and displays systolic and diastolic pressure (mmHg) and pulse rate (bpm) readings on an output screen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment difference in initiation of statin therapy</measure>
    <time_frame>At month 36</time_frame>
    <description>Assessment will be based on the current Canadian Cardiovascular Society Guidelines</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Completeness of clinic attendance and data collection and provision of fasting blood samples for planned tests.</measure>
    <time_frame>At months -3, -0.5, and then at months 0, 3, 6, 9,12, 15, 18, 21, 24, 27, 30, 33 and 36</time_frame>
    <description>This will be used as a measure of retension</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum lipids: total cholesterol, LDL-chol, HDL-chol, and Triglycerides</measure>
    <time_frame>At months -3, -0.5, and then at months 0, 3, 6, 9,12, 15, 18, 21, 24, 27, 30, 33 and 36</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hemoglobin A1c</measure>
    <time_frame>At months -3, -0.5, 0, 3, 6, 9,12, 15, 18, 21, 24, 27, 30, 33 and 36</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>At months 0,12, 24 and 36</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Urinary analyses</measure>
    <time_frame>At months 0 and 36</time_frame>
    <description>24 hr urine samples will be analyzed for creatinine, urea, C-peptide, minerals, electrolytes and other dietary biomarkers</description>
  </other_outcome>
  <other_outcome>
    <measure>Fasting blood Glucose</measure>
    <time_frame>At months -3, -0.5, 0, 3, 6, 9,12, 15, 18, 21, 24, 27, 30, 33 and 36</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>At months -3, -0.5, and then at months 0, 3, 6, 9,12, 15, 18, 21, 24, 27, 30, 33 and 36</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Treadmill testing</measure>
    <time_frame>At month -1, and end of years 1, 2, and 3</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Diet history</measure>
    <time_frame>At months -3, -0.5, and then at months 0, 3, 6, 9,12, 15, 18, 21, 24, 27, 30, 33 and 36</time_frame>
    <description>7-day food records brought in at 3 monthly intervals will be analysed for macro and micro nutrient intakes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exercise history</measure>
    <time_frame>At months -3, -0.5, and then at months 0, 3, 6, 9,12, 15, 18, 21, 24, 27, 30, 33 and 36</time_frame>
    <description>7-day exercise/ activity records of the week prior to each study visit will be assessed for the type and duration of activity.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pedometer records</measure>
    <time_frame>At months -3, -0.5, and then at months 0, 3, 6, 9,12, 15, 18, 21, 24, 27, 30, 33 and 36</time_frame>
    <description>These will be assessed for the daily step count over a 7-day period prior to the specified time points for the test group only.</description>
  </other_outcome>
  <other_outcome>
    <measure>Survey on quality of life</measure>
    <time_frame>At months 0 and 36.</time_frame>
    <description>This will be done using a Medical Outcomes Study 36-Item Short Form Questionnaire (SF-36).</description>
  </other_outcome>
  <other_outcome>
    <measure>Palatability (taste) of diet</measure>
    <time_frame>At months 3, 6, 9,12, 15, 18, 21, 24, 27, 30, 33 and 36</time_frame>
    <description>This will be measure on a scale to 1 to 10. 1 being 'strongly dislike' and 10 being 'like very much'. Participants will rate the taste (palatability) of the study diet and dietary components.</description>
  </other_outcome>
  <other_outcome>
    <measure>Satiety</measure>
    <time_frame>At months 3, 6, 9,12, 15, 18, 21, 24, 27, 30, 33 and 36</time_frame>
    <description>Using a 9-point bipolar semantic scale where -4 is extremely hungry, 0 is neutral and +4 is uncomfortably full, participants will rate their overall feeling of satiety for the previous week</description>
  </other_outcome>
  <other_outcome>
    <measure>Sustainability of diet (preparedness to continue on the diet)</measure>
    <time_frame>At months 33 and 36</time_frame>
    <description>Participants' preparedness to continue on the diet will be measured on a scale of 1 to 10. 1 = diet not sustainable; 10 = diet very sustainable</description>
  </other_outcome>
  <other_outcome>
    <measure>Genetic testing for specific genes</measure>
    <time_frame>Week 0 or any other time point</time_frame>
    <description>One time sample collection of buffy coat (from white cells) for future study on gene, diet, exercise and chronic disease relationship</description>
  </other_outcome>
  <other_outcome>
    <measure>Complete blood count (CBC)</measure>
    <time_frame>Months 0, 12, 24 and 36</time_frame>
    <description>Health check at start and yearly intervals</description>
  </other_outcome>
  <other_outcome>
    <measure>Renal function tests</measure>
    <time_frame>Months 0, 12, 24 and 36</time_frame>
    <description>Health check at start and yearly intervals</description>
  </other_outcome>
  <other_outcome>
    <measure>Liver function tests</measure>
    <time_frame>Months 0, 12, 24 and 36</time_frame>
    <description>Health check at start and yearly intervals</description>
  </other_outcome>
  <other_outcome>
    <measure>Prostatic specific antigen (PSA)</measure>
    <time_frame>Months 0, 12, 24 and 36</time_frame>
    <description>Health check at start and yearly intervals for male participants</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Hypercholesterolemia</condition>
  <condition>Type 2 Diabetes</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Test: Portfolio Plus Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive advice that will conform to the current therapeutic diet appropriate for hypercholesterolemia (ie &lt;7% of energy from saturated fat, &lt;200mg/d cholesterol) PLUS the combination of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat, and selection of low glycemic index foods and be given the Laval exercise program—a standardized physical activity/exercise component supervised by trained kinesiologists (exercise physiologists).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control: DASH-like (high fibre) Diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive advice to follow a DASH-like diet of whole grains, and low-fat dairy products with fruits and vegetables and a Health Canada Physical Activity pamphlet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Portfolio Plus Diet</intervention_name>
    <description>Diet: Foods on the dietary portfolio plan will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley, oat bran breads and soups) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other soy meat analogues, soy milks, yogurts and cheese) and 22.5 g peanuts or equivalent of tree nuts/1000 kcal (Table 1A) and increased MUFA (as olive and canola oils, avocados, nuts, margarine and salad dressings). The glycemic index will be reduced from 83 to 70 GI units (bread scale). Study visits after randomization will be every 3 months.
Exercise: A physical activity/exercise program encouraging 150 minutes of exercise. This is based on the exercise program developed at the Quebec Heart and Lung Institute.</description>
    <arm_group_label>Test: Portfolio Plus Diet</arm_group_label>
    <other_name>Dietary Portfolio of cholesterol-lowering foods</other_name>
    <other_name>Enhanced protfolio</other_name>
    <other_name>Low Glycemic Index Portfolio</other_name>
    <other_name>Laval exercise program</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>DASH-like (high fiber) Diet</intervention_name>
    <description>Diet: Participants will be encouraged to follow a diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals), reduce meat consumption, choose low fat dairy foods and a control margarine.
Exercise: A pamphlet (Canada's Physical Activity Guide, Health Canada) encouraging increased physical activity will be provided.</description>
    <arm_group_label>Control: DASH-like (high fibre) Diet</arm_group_label>
    <other_name>modified DASH diet</other_name>
    <other_name>high fibre diet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        A) Inclusion Criteria:

          -  Eligible participants will be

               -  men over 21 years

               -  post-menopausal women

        Having a BMI 25-40 kg/m2 whose body weight has remained constant (within ±2kg) over the
        last 3 months preceding the onset of the study and who have measurable arterial thickening
        (&gt;1.0mm) at screening as assessed by ultrasound.

        They will include those who:

          1. have type 2 diabetes with one of the following:

               -  raised LDL-cholesterol (in accordance with the 2012 Canadian Cardiovascular
                  Society Guidelines)

               -  raised BP (≥145/95mmHg), or

               -  active smoking

          2. non-diabetic subjects post MI or post percutaneous coronary intervention
             (angioplasty) on statin therapy;

          3. are hypercholesterolemic and are treated with statins or have been prescribed statins
             but are not taking it because they are either unable(intolerant) or unwilling to take
             statin drugs.

        B) Exclusion Criteria:

          -  Individuals with the following conditions will be excluded:

             --cardiovascular disease that precludes exercise e.g.

          -  recent stroke or

          -  recent myocardial infarction or

             --cardiac condition that severely compromises normal function

          -  mitral valve disease,

          -  heart failure--grades 2-4 (based on New York Heart Association classification),

          -  severe angina sufficient to prevent any form of physical activity

          -  other conditions preventing exercise.

               -  clinical diagnosis of familial hypercholesterolemia

               -  secondary causes of hypercholesterolemia

          -  hypothyroidism (unless treated and on a stable dose of L-thyroxine)

          -  clinically significant renal or liver disease

               -  uncontrolled blood pressure

               -  major disability

               -  disorder requiring continuous medical attention (on steroids or Coumadin)and
                  treatment, such as:

          -  chronic heart failure

          -  liver disease

          -  renal failure or

          -  cancer (except non-melanoma skin cancer--basal cell, squamous cell)

               -  chronic infections (bacterial or viral)

               -  chronic inflammatory diseases (eg. lupus, ulcerative colitis, crohn's disease,
                  celiac disease or gluten sensitivity)

               -  other autoimmune disease

               -  major surgery &lt;6 months prior to randomization

               -  newly diagnosed with diabetes (&lt;3 months)

               -  alcohol consumption &gt;3 drinks/d

               -  not suitable for MRI examination because of metal implants or claustrophobia

               -  food allergies or sensitivity to study foods or study food components (eg. tree
                  nuts, peanuts, soy, wheat, gluten, oats, eggs, milk)

               -  already following a portfolio-like diet or have a structured exercise program

               -  do not have a family doctor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Jenkins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Risk Factor Modification Centre, St. Michael's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benoit Lamarche, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Laval University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Jones, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jiri Frohlich, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David J Jenkins, MD</last_name>
    <phone>416-867-7475</phone>
    <email>NutritionProject@smh.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cyril Kendall, PhD</last_name>
    <phone>416-978-6527</phone>
    <email>cyril.kendall@utoronto.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Healthy Heart Lipid Clinic, St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jiri Frohlich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3T 6C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Jones, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Peter Jones, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Risk Factor Modification Centre, St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David J A Jenkins, MD PhD</last_name>
      <phone>416-867-7475</phone>
      <email>NutritionProject@smh.ca</email>
    </contact>
    <contact_backup>
      <last_name>Dorothea A Faulkner, PhD</last_name>
      <phone>416-867-7460</phone>
      <phone_ext>8175</phone_ext>
      <email>FaulknerD@smh.ca</email>
    </contact_backup>
    <investigator>
      <last_name>David J A Jenkins, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cyril Kendall, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Josse, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lawrence Leiter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Sievenpiper, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anish Kirpalani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Nutraceuticals and Functional Foods, Laval University</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoit Lamarche, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Benoit Lamarche, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, Erdman JW Jr, Kris-Etherton P, Goldberg IJ, Kotchen TA, Lichtenstein AH, Mitch WE, Mullis R, Robinson K, Wylie-Rosett J, St Jeor S, Suttie J, Tribble DL, Bazzarre TL. AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation. 2000 Oct 31;102(18):2284-99.</citation>
    <PMID>11056107</PMID>
  </reference>
  <reference>
    <citation>Anderson TJ, Grégoire J, Hegele RA, Couture P, Mancini GB, McPherson R, Francis GA, Poirier P, Lau DC, Grover S, Genest J Jr, Carpentier AC, Dufour R, Gupta M, Ward R, Leiter LA, Lonn E, Ng DS, Pearson GJ, Yates GM, Stone JA, Ur E. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013 Feb;29(2):151-67. doi: 10.1016/j.cjca.2012.11.032. Review.</citation>
    <PMID>23351925</PMID>
  </reference>
  <reference>
    <citation>Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, Sparler S, Armstrong WT, Ports TA, Kirkeeide RL, Hogeboom C, Brand RJ. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998 Dec 16;280(23):2001-7. Erratum in: JAMA 1999 Apr 21;281(15):1380.</citation>
    <PMID>9863851</PMID>
  </reference>
  <reference>
    <citation>Jenkins DJ, Chiavaroli L, Wong JM, Kendall C, Lewis GF, Vidgen E, Connelly PW, Leiter LA, Josse RG, Lamarche B. Adding monounsaturated fatty acids to a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia. CMAJ. 2010 Dec 14;182(18):1961-7. doi: 10.1503/cmaj.092128. Epub 2010 Nov 1.</citation>
    <PMID>21041432</PMID>
  </reference>
  <reference>
    <citation>Jenkins DJ, Kendall CW, McKeown-Eyssen G, Josse RG, Silverberg J, Booth GL, Vidgen E, Josse AR, Nguyen TH, Corrigan S, Banach MS, Ares S, Mitchell S, Emam A, Augustin LS, Parker TL, Leiter LA. Effect of a low-glycemic index or a high-cereal fiber diet on type 2 diabetes: a randomized trial. JAMA. 2008 Dec 17;300(23):2742-53. doi: 10.1001/jama.2008.808.</citation>
    <PMID>19088352</PMID>
  </reference>
  <reference>
    <citation>Jenkins DJ, Kendall CW, Augustin LS, Mitchell S, Sahye-Pudaruth S, Blanco Mejia S, Chiavaroli L, Mirrahimi A, Ireland C, Bashyam B, Vidgen E, de Souza RJ, Sievenpiper JL, Coveney J, Leiter LA, Josse RG. Effect of legumes as part of a low glycemic index diet on glycemic control and cardiovascular risk factors in type 2 diabetes mellitus: a randomized controlled trial. Arch Intern Med. 2012 Nov 26;172(21):1653-60.</citation>
    <PMID>23089999</PMID>
  </reference>
  <reference>
    <citation>Jenkins DJ, Kendall CW, Faulkner D, Vidgen E, Trautwein EA, Parker TL, Marchie A, Koumbridis G, Lapsley KG, Josse RG, Leiter LA, Connelly PW. A dietary portfolio approach to cholesterol reduction: combined effects of plant sterols, vegetable proteins, and viscous fibers in hypercholesterolemia. Metabolism. 2002 Dec;51(12):1596-604.</citation>
    <PMID>12489074</PMID>
  </reference>
  <reference>
    <citation>Borel AL, Nazare JA, Smith J, Alméras N, Tremblay A, Bergeron J, Poirier P, Després JP. Visceral and not subcutaneous abdominal adiposity reduction drives the benefits of a 1-year lifestyle modification program. Obesity (Silver Spring). 2012 Jun;20(6):1223-33. doi: 10.1038/oby.2011.396. Epub 2012 Jan 19.</citation>
    <PMID>22262155</PMID>
  </reference>
  <reference>
    <citation>Borel AL, Nazare JA, Smith J, Alméras N, Tremblay A, Bergeron J, Poirier P, Després JP. Improvement in insulin sensitivity following a 1-year lifestyle intervention program in viscerally obese men: contribution of abdominal adiposity. Metabolism. 2012 Feb;61(2):262-72. doi: 10.1016/j.metabol.2011.06.024. Epub 2011 Aug 23.</citation>
    <PMID>21864868</PMID>
  </reference>
  <reference>
    <citation>Pelletier-Beaumont E, Arsenault BJ, Alméras N, Bergeron J, Tremblay A, Poirier P, Després JP. Normalization of visceral adiposity is required to normalize plasma apolipoprotein B levels in response to a healthy eating/physical activity lifestyle modification program in viscerally obese men. Atherosclerosis. 2012 Apr;221(2):577-82. doi: 10.1016/j.atherosclerosis.2012.01.023. Epub 2012 Jan 20.</citation>
    <PMID>22321874</PMID>
  </reference>
  <reference>
    <citation>Liu S, Willett WC, Stampfer MJ, Hu FB, Franz M, Sampson L, Hennekens CH, Manson JE. A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in US women. Am J Clin Nutr. 2000 Jun;71(6):1455-61.</citation>
    <PMID>10837285</PMID>
  </reference>
  <reference>
    <citation>Pereira MA, O'Reilly E, Augustsson K, Fraser GE, Goldbourt U, Heitmann BL, Hallmans G, Knekt P, Liu S, Pietinen P, Spiegelman D, Stevens J, Virtamo J, Willett WC, Ascherio A. Dietary fiber and risk of coronary heart disease: a pooled analysis of cohort studies. Arch Intern Med. 2004 Feb 23;164(4):370-6.</citation>
    <PMID>14980987</PMID>
  </reference>
  <reference>
    <citation>Keys A, Aravanis C, Blackburn HW, Van Buchem FS, Buzina R, Djordjević BD, Dontas AS, Fidanza F, Karvonen MJ, Kimura N, Lekos D, Monti M, Puddu V, Taylor HL. Epidemiological studies related to coronary heart disease: characteristics of men aged 40-59 in seven countries. Acta Med Scand Suppl. 1966;460:1-392.</citation>
    <PMID>5226858</PMID>
  </reference>
  <reference>
    <citation>Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow S, Greenberg I, Golan R, Fraser D, Bolotin A, Vardi H, Tangi-Rozental O, Zuk-Ramot R, Sarusi B, Brickner D, Schwartz Z, Sheiner E, Marko R, Katorza E, Thiery J, Fiedler GM, Blüher M, Stumvoll M, Stampfer MJ; Dietary Intervention Randomized Controlled Trial (DIRECT) Group.. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med. 2008 Jul 17;359(3):229-41. doi: 10.1056/NEJMoa0708681. Erratum in: N Engl J Med. 2009 Dec 31;361(27):2681.</citation>
    <PMID>18635428</PMID>
  </reference>
  <reference>
    <citation>Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Desvarieux M, Ebrahim S, Fatar M, Hernandez Hernandez R, Kownator S, Prati P, Rundek T, Taylor A, Bornstein N, Csiba L, Vicaut E, Woo KS, Zannad F; Advisory Board of the 3rd Watching the Risk Symposium 2004, 13th European Stroke Conference.. Mannheim intima-media thickness consensus. Cerebrovasc Dis. 2004;18(4):346-9. Epub 2004 Nov 2. Review.</citation>
    <PMID>15523176</PMID>
  </reference>
  <reference>
    <citation>Jenkins DJ, Kendall CW, Faulkner DA, Nguyen T, Kemp T, Marchie A, Wong JM, de Souza R, Emam A, Vidgen E, Trautwein EA, Lapsley KG, Holmes C, Josse RG, Leiter LA, Connelly PW, Singer W. Assessment of the longer-term effects of a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia. Am J Clin Nutr. 2006 Mar;83(3):582-91.</citation>
    <PMID>16522904</PMID>
  </reference>
  <reference>
    <citation>The DASH diet. Dietary Approaches to Stop Hypertension. Lippincotts Prim Care Pract. 1998 Sep-Oct;2(5):536-8.</citation>
    <PMID>9791393</PMID>
  </reference>
  <reference>
    <citation>Murie-Fernandez M, Irimia P, Toledo E, Martínez-Vila E, Buil-Cosiales P, Serrano-Martínez M, Ruiz-Gutiérrez V, Ros E, Estruch R, Martínez-González MÁ; PREDIMED Investigators.. Carotid intima-media thickness changes with Mediterranean diet: a randomized trial (PREDIMED-Navarra). Atherosclerosis. 2011 Nov;219(1):158-62. doi: 10.1016/j.atherosclerosis.2011.06.050. Epub 2011 Jul 6.</citation>
    <PMID>21802081</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 31, 2017</lastchanged_date>
  <firstreceived_date>May 26, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arterial plaque</keyword>
  <keyword>Magnetic resonance imaging (MRI)</keyword>
  <keyword>Portfolio diet</keyword>
  <keyword>Dietary modification</keyword>
  <keyword>Dietary trials</keyword>
  <keyword>hypercholesterolemia</keyword>
  <keyword>diabetes</keyword>
  <keyword>exercise</keyword>
  <keyword>cardiovascular disease risk</keyword>
  <keyword>glycemic index (GI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
